2,5-Dichloro-4,6-dimethylnicotinonitrile | CAS:91591-63-8

We serve 2,5-Dichloro-4,6-dimethylnicotinonitrile CAS:91591-63-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,5-Dichloro-4,6-dimethylnicotinonitrile

Chemical Name: 2,5-Dichloro-4,6-dimethylnicotinonitrile
CAS: 91591-63-8
Synonyms:
2,5-dichloro-4,6-dimethylpyridine-3-carbonitrile
3-Pyridinecarbonitrile, 2,5-dichloro-4,6-dimethyl-
 
Molecular Formula: C8H6Cl2N2
Molecular Weight: 201.053
Boiling Point: 304.6±37.0 °C at 760 mmHg
Density: 1.4±0.1 g/cm3
Melting Point: 82ºC
Flash Point: 138.0±26.5 °C
 
Specification:
Appearance: Light brown solid
Assay: 98.0%min
Moisture: ≤0.5%
 
Application: Opiperidone intermediates, Opicapone is used to treat adult patients with Parkinson's disease with exercise fluctuations, and those with Parkinson's disease who cannot control their condition with current therapies.



Contact us for information like 2,5-Dichloro-4,6-Dimethylnicotinonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Pyridinecarbonitrile, 2,5-dichloro-4,6-dimethyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Pyridinecarbonitrile, 2,5-dichloro-4,6-dimethyl- Use and application,2,5-dichloro-4,6-dimethylpyridine-3-carbonitrile technical grade,usp/ep/jp grade.


Related News: The workers are demanding that Hong Kong close all border checkpoints to visitors from mainland China, saying they represent a threat to health care workers in the city.1-Chloro-4-fluorobutane manufacturer In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.Ethyl (E)-hex-2-enoate supplier On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday.5-Cyanoindole vendor Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.